Clinicopathological Parameters in Patient Selection for Cytoreductive Surgery and Hyperthermic Intraperitoneal Chemotherapy for Colorectal Cancer Metastases A Meta-analysis
| Autor: | Anne M. Schrama, Josefien P. van Olmen, Erienne M.V. de Cuba, R. Kwakman, Elisabeth A. te Velde, Geert Kazemier, René H. J. Otten, Elly S.M. de Lange-de Klerk |
|---|---|
| Přispěvatelé: | Surgery, CCA - Biomarkers, Epidemiology and Data Science, EMGO - Musculoskeletal health, Other Research, Pathology |
| Jazyk: | angličtina |
| Rok vydání: | 2016 |
| Předmět: |
Oncology
medicine.medical_specialty Colorectal cancer medicine.medical_treatment 03 medical and health sciences 0302 clinical medicine Cytoreduction Surgical Procedures Internal medicine otorhinolaryngologic diseases Humans Medicine Peritoneal Neoplasms Survival analysis Chemotherapy business.industry Patient Selection Cancer Hyperthermia Induced medicine.disease Survival Analysis Surgery Chemotherapy Cancer Regional Perfusion 030220 oncology & carcinogenesis Meta-analysis 030211 gastroenterology & hepatology Hyperthermic intraperitoneal chemotherapy Colorectal Neoplasms business Cytoreductive surgery |
| Zdroj: | Kwakman, R, Schrama, A M, van Olmen, J P, Otten, R H, de lange-de Klerk, E S, de Cuba, E M, Kazemier, G & Velde, E A T 2016, ' Clinicopathological Parameters in Patient Selection for Cytoreductive Surgery and Hyperthermic Intraperitoneal Chemotherapy for Colorectal Cancer Metastases A Meta-analysis ', Annals of Surgery, vol. 263, no. 6, pp. 1102-1111 . https://doi.org/10.1097/SLA.0000000000001593 Annals of Surgery, 263(6), 1102-1111. Lippincott Williams and Wilkins |
| ISSN: | 0003-4932 |
| DOI: | 10.1097/SLA.0000000000001593 |
| Popis: | To improve patient selection for cytoreductive surgery (CRS) and hyperthermic intraperitoneal chemotherapy (HIPEC) by evaluating various preoperatively assessable clinicopathological parameters as markers for survival after CRS and HIPEC.Peritoneal metastases (PMs) originating from colorectal cancer are treated with CRS and HIPEC. Despite increasing survival, high morbidity and mortality warrant selection of patients with optimal benefit from this treatment. Many studies report a number of variables to be associated with survival after CRS and HIPEC, but no definitive analysis has been made to validate various markers.In concordance with PRISMA guidelines, we performed a literature search encompassing 4110 articles to select 50 articles that reported the influence of 1 or more clinicopathological variables on overall survival after CRS and HIPEC. In absence of RCTs, 25 cohort studies could be used to perform a meta-analysis on 10 prognostic variables.We determined that concurrent liver metastasis, lymph node metastasis, Eastern Cooperative Oncology Group score, tumor differentiation, and signet ring cell histology are all negative prognostic variables on overall survival after CRS and HIPEC. Conversely, sex and location of primary could not be validated as prognostic markers. More research is required to make definitive conclusions about neoadjuvant chemotherapy, onset of PMs, and mucinous histology.Current clinical practice, which selects patients based on extraperitoneal metastasis, lymph node stage, performance status, and tumor histology, is validated by our pooled analysis. Our data merit further research into neoadjuvant chemotherapy in the setting of CRS and HIPEC for PMs. |
| Databáze: | OpenAIRE |
| Externí odkaz: |
|